anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ETHNOPHARMACOLOGICAL RELEVANCE: Jinmaitong (JMT) is a prescription of Traditional Chinese Medicine that is composed of 12 crude drugs. It has been used in the treatment of diabetic neuropathic pain (DNP) for more than 30 years.
AIM OF STUDY: Microglia are thought to play an important role in neuropathic pain. This study aimed to evaluate the protective effect of JMT against DNP and to investigate the underlying mechanisms in which the microglia and JAK2/STAT3 signaling pathway were mainly involved.
MATERIALS AND METHODS: The chemical composition of JMT was analyzed using liquid chromatography tandem mass spectrometry. The diabetes model was constructed using 11 to 12-week-old male Zucker diabetic fatty (ZDF) rat (fa/fa). The model rats were divided into 5 groups and were given JMT at three dosages (11.6, 23.2, and 46.4 g/kg, respectively, calculated as the crude drug materials), JAK inhibitor AG490 (positive drug, 10 μg/day), and placebo (deionized water), respectively, for eight weeks (n = 6). Meanwhile, Zucker lean controls (fa/+) were given a placebo (n = 6). Body weight was tested weekly and blood glucose was monitored every 2 weeks. The mechanical allodynia and heat hyperalgesia were assessed using mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) tests. After treatment, the microglia activation marker Iba-1, CD11B, CD68, neuroinflammatory mediators, and mediators of the JAK2/STAT3 signaling pathway were compared between different groups. The mRNA and protein levels of target genes were assessed by quantitative real-time PCR and Western Blot, respectively.
RESULTS: We found that JMT significantly inhibited the overactivation of microglia in spinal cords, and suppressed neuroinflammation of DNP model rats, thereby ameliorating neurological dysfunction and injuries. Furthermore, these effects of JMT could be attributed to the inhibition of the JAK2/STAT3 signaling pathway.
CONCLUSIONS: Our findings suggested that JMT effectively ameliorated DNP by modulating microglia activation via inhibition of the JAK2/STAT3 signaling pathway. The present study provided a basis for further research on the therapeutic strategies of DNP.
PURPOSE: To present a presumed case of non-paraneoplastic autoimmune retinopathy (nPAIR) following COVID-19 in a healthy woman.
METHODS: A single case was evaluated and followed for 32 months.
RESULTS: A healthy 32-year-old woman presented with photopsia and paracentral scotoma (OU) after a recent COVID-19 infection. Past medical history and family history were unremarkable. Her visual acuity was normal (OU). Retinal atrophy, mild disc pallor, and foveal reflex attenuation were observed (OU). Optical coherence tomography (OCT) scans showed outer nuclear layer thinning and ellipsoid zone disruption (OU). The visual field test showed blind spot enlargement and arcuate scotomas (OU). Uveitis workup and underlying malignancy investigations were negative. A diagnosis of nPAIR was presumed. At the time, she refused therapy, and 20 months later, her visual acuity was stable, but there were progressive retinal atrophic changes and visual field constriction. After initiation of glucocorticoids and immunosuppressive therapy, flashing lights completely disappeared, her visual field was stabilized without progression, and OCT scans showed partial recovery of ellipsoid zone.
CONCLUSION: SARS-CoV-2 infection may be a trigger for nPAIR in susceptible individuals, but further research is needed to determine this association.
Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) \& Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
BACKGROUND: We assessed the safety and efficacy of oral antibiotic step-down therapy for uncomplicated gram-negative blood stream infections in solid-organ transplant recipients.
METHODS: We identified all solid-organ transplant recipients within the Massachusetts General and Brigham and Women's Hospital systems from 2016 to 2021 with uncomplicated gram-negative bacteremia involving an organism susceptible to an acceptably bioavailable oral antibiotic agent. Using inverse probability of treatment-weighted models based on propensity scores adjusting for potential clinical confounders, we compared outcomes of those transitioned to oral antibiotics with those who continued intravenous (IV) therapy for the duration of treatment. Primary endpoints were mortality, bacteremia recurrence, and reinitiation of IV antibiotics. Secondary endpoints included length of stay, Clostridioides difficile infection, treatment-associated complications, and tunneled central venous catheter placement.
RESULTS: A total of 120 bacteremia events from 107 patients met inclusion criteria in the oral group and 42 events from 40 patients in the IV group. There were no significant differences in mortality, bacteremia recurrence, or reinitiation of IV antibiotics between groups. Patients transitioned to oral antibiotics had an average length of stay that was 1.97 days shorter (95% confidence interval [CI], -.39 to 3.56 days; P = .005). Odds of developing C. difficile and other treatment-associated complications were 8.4 times higher (95% CI, 1.5-46.6; P = .015) and 6.4 times higher (95% CI, 1.9-20.9; P = .002), respectively, in the IV group. Fifty-five percent of patients in the IV group required tunneled catheter placement. There was no difference in treatment duration between groups.
CONCLUSIONS: Oral step-down therapy was effective and associated with fewer treatment-related adverse events.
The prognosis of recurrent or metastatic esophageal squamous cell cancer is poor. However, there is still no standard chemotherapy regimen recommended for this disease because of the lack of trails. Currently, anti-angiogenesis therapy had been proved to improve the survival successfully in colorectal cancer, non-small cell lung cancer, breast cancer, glioma and kidney cancer. Recent studies showed that the high level of VEGF was negative correlated with the prognosis of esophageal cancer. Endostar, as a novel endogenous angiogenesis inhibitors, was proved to significantly inhibited the proliferation and metastasis in esophageal cell lines and animal models. A retrospective study also reported the safety and efficacy of the combination therapy of paclitaxel liposome and recombinant human endostatin. Based on the basis above, we designed this phase Ⅱ study to evaluate the efficacy and safety of endostar combined with paclitaxel and nedaplatin as first-line therapy in treating patients with recurrent or metastatic esophageal squamous cell cancer.
The invention is a method of making a composite material (from a route given by the phase behavior of a suitable chemical system that is described in a phase diagram), which comprises at least one amphifilic component and at least one polymer component. It comprises providing a mixture of at least one polymer and at least one amphifilic compound in a volatile solvent or solvent mixture as well as providing a phase diagram of the chemical system that describes how the components of the chemical system interact in thermodynamic stable phases as a function temperature, concentration and pressure. The polymer should be a homopolymer, a random block copolymer or a mixture thereof, preferably biodegradable. The amphifilic compound has the ability to form a bilayer-containing phase. The solvent is removed from the mixture by a process selected from the phase diagram in dependence of the final composite material to be achieved, whereby a material is formed, such as liquid extraction against a second solvent, or by spraying. It also relates to the composite material, in particular particles, solid implants, semi-solid, gel-like matrices, useful for applications such as encapsulation of therapeutically active components or surface coating.
The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
In this study, a computer based word repetition protocol was administered at the distance to 12 pure anomic patients in the chronic stage of the disease. The to be repeated words were presented alongside the corresponding pictures. The timing of word and picture presentation was manipulated in order to investigate the suitability of classical conditioning to reteach the association between pictures and their names. Data were analyzed at the group and at the single subject level with the aim of establishing the relative efficacy of the conditioned and non-conditioned word-repetition modality and the cognitive features predicting therapy success. In keeping with preliminary results obtained on a single case study, conditioning turned out to improve therapy gain at the group level. Moreover, hints were found suggesting less generalization to untreated words in conditioned compared to non-conditioned training. Non-word repetition skills was the only feature in the participants cognitive profile which was reliably linked to the therapy outcome.
Atherosclerotic cardiovascular disease (ASCVD) is one of the most devastating consequences of Diabetes Mellitus (DM), especially when combined with other comorbid conditions such as dyslipidemia and hypertension. To lessen the probability of ASCVD, modifying an individual's lifestyle and regulating one's lipid profile, blood pressure, and glucose levels are all beneficial approaches that decrease the risk of ASCVD occurrence. Numerous diseases, including hypertension, dyslipidemia, and diabetes mellitus, have been shown to be significantly influenced by both oxidative stress and inflammation. Curcumin is thought to regulate blood pressure, lipid profile, blood glucose levels. Moreover, It is claimed that curcumin can alleviate inflammation and oxidative stress. Curcumin is therefore suggested to have a beneficial role in lowering the risk of atherosclerotic cardiovascular diseases.
The aim of this project was to determine the effect of the burn prevention and first aid mobile application developed for families living in tent cities and container houses after the earthquake on the burn prevention and first aid knowledge of families and the development of burns in the first two months after the mobile application.The research was planned as a prospective, two-arm (1:1), randomized controlled trial. This randomized controlled trial will be reported according to CONSORT guidelines. The research population will consist of families living in tent cities and container houses in Şanlıurfa. As a result of the power analysis performed in the G\*Power program, the sample group will consist of 30 families from the tent city and 30 families from the container city, taking into account the losses with a power of 90% and a maximum bidirectional 5% type error. All of the families (30 mobile application-study group; 30 control group) who make up the sample of the research will be given a training (powerpoint presentation) prepared by the researcher in line with the literature, and burn prevention and first aid practices will be explained and their questions will be answered. Then, the training to be given with the mobile application will be downloaded to the phones of the families in the experimental group and the training will continue through the application. Thus, families will be able to access the training from the mobile application at any time after the training. The primary results of the research are the effect of the mobile application on burn prevention and first aid knowledge. The secondary outcome of the study is the effect of the mobile application on the development of burns in the first two months after the mobile application. In the study, data will be collected with the "Descriptive Characteristics Form", "Information Form on Burn Prevention and First Aid" and "Burn Development Follow-up Form", which include the descriptive information of the families. The data obtained from the study will be analyzed in computer environment.
This phase I/IIa study will be composed of a Phase I study, which includes 14 days of treatment with AR100DP1 followed by 2 weeks of follow-up period to find the maximum tolerated dose (MTD) of AR100DP1 and a following single-arm Phase IIa study with 28 days of treatment followed by 2 weeks of follow-up period to evaluate the efficacy of AR100DP1 with the recommended Phase II dose (RP2D) in treating atopic dermatitis on target lesion. Target lesion area(s) is defined as one or multiple patches of lesion areas selected by the investigator for topical administration of AR100DP1. The size of target lesion area(s) is 0.5-5% body surface area (BSA) and the maximum is 750 cm2 (maximal treated area, inclusive) in this study. Eligible healthy subjects in Phase I will have the test skin area(s) of 750 cm2 from chest and abdomen. Eligible subjects with mild to moderate AD in Phase IIa will have target lesion area(s) selected by the investigator. The skin area treated with AR100DP1 will be recorded for AR100DP1 topical administration before dosing. AR100DP1 should be topically administered twice daily on the test skin area(s) of 750 cm2 of eligible healthy subjects for 14 days in Phase I study. The administration of AR100DP1 should be topically applied twice daily on target lesion area(s) (0.5-5% BSA, maximum as 750 cm2, inclusive) of eligible subjects with mild to moderate AD for 28 days in Phase IIa study.
CD95L is a transmembrane glycoprotein that acts through cell contact. After cleavage by metalloproteases, a soluble CD95L (cleaved CD95L or cl-CD95L) is released into the bloodstream. This soluble ligand contributes to aggravate chronic inflammatory disorders such as systemic lupus erythematosus (SLE) and may exert pro-oncogenic functions by promoting the survival of ovarian and breast cancers and chemotherapy resistance of lung cancers. The inventors hypothesized that monoclonal antibodies targeting the Metalloprotease-Cleavage Sites of CD95L (MCSCs) encompassing amino-acid residues 103 to 145 could prevent the access to metalloproteases and inhibit CD95L shedding. Therefore, they generated antibodies covering different epitopes within MCSC and two of them (i.e., 3C7 and 9F5), efficiently abrogated the cleavage of CD95L by MMP2 and MMP3. The results indicate that these MCSC- targeting mAbs can compete with MMPs and represent original and attractive therapeutic options to block the release of the inflammatory s-CD95L.
The mock comparison follows the in-school format of 16 15-minute sessions; scheduled 3 sessions/week. The content is provided by trained health educators and includes skills practice (i.e., handwashing and brushing teeth) and health promotion topics of nutrition, healthy snacks, preventing colds, and safe exercise.
FIELD: medicine, pharmacy, chemistry of peptides. SUBSTANCE: composition has a purified peptide taken at effective dose or a mixture of two or more different peptides containing up to 30 amino acids. Composition can contain also derivatives of these amino acids bearing additional chemical groups. Peptides include amino acid sequence that has at least by 50% homology of the following amino acid sequence: NH 2 -Thr- -Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu-COOH (HEP-I). Apart from, composition has a purified peptide or a mixture of two or more different peptides containing up to 30 amino acids or their derivatives bearing additional chemical groups. These peptides include an amino acid sequence where at least five ones have 100% homology of HEP-I. Also, a composition has a pharmaceutically acceptable carrier. EFFECT: enhanced effectiveness and safety of a composition proposed. 2 cl, 3 dwg, 4 tbl, 2 ex
Methotrexate can cause severe and potentially irreversible hepatotoxicity, including fibrosis, cirrhosis, and fatal liver failure [see Adverse Reactions (6.1)]. The safety of methotrexate tablets in patients with hepatic disease is unknown.

The risk of hepatotoxicity is increased with heavy alcohol consumption. In patients with psoriasis, fibrosis or cirrhosis may occur in the absence of symptoms or abnormal liver tests; the risk of hepatotoxicity appears to increase with total cumulative dose and generally occurs after receipt of a total cumulative dose of 1.5 g or more.

Monitor liver tests at baseline, periodically during treatment and as clinically indicated. Withhold or discontinue methotrexate tablets taking into account the importance of methotrexate tablet treatment in the context of the severity of the disease being treated, the severity of the adverse drug reaction, and availability of alternative therapy [see Dosage and Administration (2.6)].
Patients will receive 2 cycles of ex-vivo expanded allogeneic γδT cells treatments, at 14 days' intervals, each cycle has 2 infusions. Ex-vivo expanded γδT cells are transfused to patients in a dosage escalated manner (Dose escalation, 1×107, 3×107, 9×107 per kg of body weight).
Described embodiments provide systems and methods for performing cancer whole genome and transcriptome sequencing (cWGTS). A plurality of datasets can be generated based on sequencing of a tumor sample and a healthy control germline sample. A plurality of databases, comprising a first, second and third database, can be accessed. An RNA gene expression analysis can be performed to generate a first plurality of outputs. A DNA ploidy and allelic imbalance analysis can be performed to generate a second plurality of outputs. A variant calling analysis can be performed to generate a third plurality of outputs. A workflow may be implemented. Cohort classification scores and disease-specific classification scores for each individual level output in each of the first, second, and third pluralities of outputs can be generated. A report can be generated and provided to one or more users.
Sodium serves as one of the primary cations in the central nervous system, playing a crucial role in maintaining normal brain function. In this study, we investigated alterations in sodium concentrations in the brain and/or cerebrospinal fluid across multiple models, including an aging model, a stroke model, a nitroglycerin (NTG)-induced rat migraine model, a familial hemiplegic migraine type 2 (FHM2) mouse model, and a transgenic mouse model of Alzheimer's disease (AD). Our results reveal that older rats exhibited higher sodium concentrations in cerebrospinal fluid (CSF), plasma, and various brain regions compared to their younger counterparts. Additionally, findings from the stroke model demonstrated a significant increase in sodium in the ischemic/reperfused region, accompanied by a decrease in potassium and an elevated sodium/potassium ratio. However, we did not detect significant changes in sodium in the NTG-induced rat migraine model or the FHM2 mouse model. Furthermore, AD transgenic mice showed no significant differences in sodium levels compared to wild-type mice in CSF, plasma, or the hippocampus. These results underscore the nuanced regulation of sodium homeostasis in various neurological conditions and aging, providing valuable insights into potential mechanisms underlying these alterations.
By means of a novel process for enzymatic elimination of oxygen, the colour changes and flavour changes occurring in foods and confectionery are prevented and the storage life is extended. Oxygen is reacted in the presence of oxalate using oxalate oxidase to give carbon dioxide and hydrogen peroxide:  O2 + oxalate @ 2 CO2 + H2O2 A possible subsequent reaction by catalase gives the following overall reaction:  1/2  O2 + oxalate @ 2 CO2 + H2O Oxalate oxidase can be added with or without oxalate direct to beverages such as fruit juices, beers, wines etc. but also, inter alia, to mayonnaises, toothpastes and chewing gums. The majority of systems show a pH favourable for the activity of oxalate oxidase of between 2.5 and 6.5. Oxalate oxidase is thermally stable up to more than 80 DEG C. By this means, protection against oxidative influence is possible even during pasteurisation. Many beverages contain the required substrate oxalate, so that after addition of oxalate oxidase, not only an elimination of the oxygen but also of the often undesirable oxalate is achieved. The process is also suitable for sugar-free media.
DAYTRANA has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see Warnings and Precautions (5.1)]. DAYTRANA can be diverted for non-medical use into illicit channels or distribution.

Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.

Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including DAYTRANA, can result in overdose and death [see Overdosage (10)], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Provided are a Hansenula engineered bacterium efficiently expressing a CA10 virus-like particle and use thereof. Said engineered bacterium comprise a recombinant vector carrying CA10 virus P1 and a 3CD genes. An original strain of the engineered bacterium is uracil-deficient Hansenula AU-0501. The P1 and 3CD genes are optimized according to a Hansenula preferred codon. Further provided is a method for preparing a CA10 virus-like particle, comprising: culturing an engineered bacterium, expressing the CA10 virus-like particle, and separating and purifying the virus-like particle by using ultrafiltration and a three-step chromatography process. Also provided is a hand-foot-and-mouth disease vaccine.